Pharmaceutical compositions and methods
This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
1. A pharmaceutical composition comprising:
at least one active agent selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
optionally, at least one auxiliary agent selected from the group consisting of oxycodone, hydrocodone, hydromorphone and methadone.
2. The pharmaceutical composition of claim 1 , wherein the composition is in a dosage form selected from the group consisting of a capsule, a tablet, a smart pill delivery device, and a smart capsule delivery device.
3. A method of treatment, comprising:
selecting a patient in need of treating a condition selected from the group consisting of nicotine, opioids, methamphetamine, and/or alcohol addiction; nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety; and nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms; and
administering to the patient in need of treating the condition an effective amount of at least one active agent selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof.
4. A method of treatment, comprising:
selecting a patient in need of treating a condition selected from the group consisting of nicotine, opioids, methamphetamine, and/or alcohol addiction; nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety; and nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms;
administering a composition comprising:
i) a therapeutic selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
ii) at least one additional therapeutic agent selected from the group consisting of:
(a) at least one anxiolytic selected from the group consisting of alprazolam, bromazepam, diazepam, lorazepam, clonazepam, temazepam, oxazepam, fluni-trazepam, triazolam, chlordiazepoxide, flurazepam, esta-zolam, nitrazepam, and pharmaceutically acceptable salts, isomers, and mixtures thereof,
(b) at least one antidepressant selected from the group consisting of citalopram, escitalopram oxalate, fluoxetine, fluvoxamine, paroxetine, sertraline, dapoxetine; venlafaxine and duloxetine; harma-line, iproniazid, isocarboxazid, nialamide, paigyline, phenelzine, selegiline, toloxatone, tranylcypromine, brofar-omine, moclobemide; amitriptyline, amoxapine, butrip-tyline, clomipramine, desipramine, dibenzepin, dothiepin, doxepin, imipramine, iprindole, lofepramine, melitracen, nortriptyline, opipramol, protriptyline, trimipramine; mapro-tiline, mianserin, nefazodone, trazodone, and pharmaceutically acceptable salts, isomers, and combinations thereof,
(c) at least one neuroleptic selected from the group consisting of Haloperidol, Droperidol, Benperidol, Triperi-dol, Melperone, Lenperone, azaperone, Domperidone, risperidone, Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine, Mesoridazine, Periciazine, Promazine, Triflupromazine, Levomepromazine, Promethazine, Pimozide, Cyamemazine, Chlorprothixene, Clopenthixol, Flupenthixol, Thiothixene, Zuclopenthixol, Clozapine, Olanzapine, Risperidone, Que-tiapine, Ziprasidone, Amisulpride, Asenapine, Paliperidone, Iloperidone, Zotepine, Sertindole, Lurasidone, Aripiprazole, and pharmaceutically acceptable salts, isomers, and combinations thereof, and
(d) combinations thereof; and
iii) at least one pharmaceutically acceptable carrier, wherein the therapeutic and the at least one additional therapeutic agent are each present in an amount which, in combination, is a therapeutically effective amount for treating the condition.
5. A method of treating nicotine, opioids, methamphetamine, and/or alcohol addiction, nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety, and/or nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms in a patient, comprising the steps of:
a) obtaining a test sample from the patient using a test sample collection unit;
b) combining said test sample with a buffering system to form a mixture in a reaction unit;
c) measuring a parameter of the mixture to determine a blank measurement;
d) combining said test sample and buffer mixture with a labeled ligand which binds cortisol in the reaction unit to produce an assay solution; or combining said test sample and buffer mixture and delivering it to a carrier containing a labeled ligand which binds cortisol in the reaction unit to produce an assay immobilized complex;
e) measuring a parameter of said assay solution or complex;
f) comparing the measurement of the assay solution relative to the blank measurement;
g) determining the patient's circulating cortisol levels based on the change of the measurement;
h) comparing the measured cortisol levels to a predetermined reference range cortisol levels, wherein when the level of cortisol is elevated relative to the predetermined reference range, then the patient has elevated cortisol, and thus is suitable for GCR (glucocorticoid receptor) antagonist therapy; and
i) when the patient is suitable, administering a composition comprising a therapeutic is selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
thereby treating nicotine, opioids, methamphetamine, and/or alcohol addiction, nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety, and/or nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms in the patient.
6. The method of claim 5 , wherein the patient's test sample is selected from the group consisting of saliva, blood, plasma, serum, urine, other bodily fluids, and combinations thereof.
7. The method of claim 5 , wherein the sample is obtained from the patient one time, selected from the group consisting of morning, noon, and evening.
8. The method of claim 5 , wherein the sample is obtained from the patient over more than one time, and the predetermined time is selected to determine the nature of the cortisol circadian rhythm, including its possible disruption or elimination, from the group consisting of morning, noon, and evening.
9. The method of claim 5 , wherein the sample is obtained from the patient over consecutive days.
10. The method of claim 5 , wherein the method is to determine the circadian cycle of the cortisol levels in the patient, and the predetermined time is selected from the group consisting of hourly, every 4 hours, every 6 hours, every 8 hours, and every 12 hours.
11. The method of claim 5 , wherein the predetermined reference range is a medically standard reference range.
12. The method of claim 5 , wherein the predetermined reference range is the patient's previously measured level.
13. The method of claim 5 , wherein the ligand is detectably labeled with a moiety selected from the group consisting of a radioisotope, a fluorophore, a quencher of fluorescence, an enzyme, an affinity tag, and an epitope tag.
14. The method of claim 5 , wherein said measuring of said parameter of said mixture and said assay solution is performed using a method selected from spectroscopic, photochemical, radiochemical, biochemical, enzymatic, immunochemical, chemical label displacement, surface plasmon resonance, fluorescence resonance energy transfer, fluorescence quenching, lateral flow, and fluorescence polarization means.